Skip to content

A pilot study of efficacy and safety of microneedling-assisted topical botulinum toxin A for the treatment of enlarged facial pores: a split-face randomized-controlled pilot study

A pilot study of efficacy and safety of microneedling-assisted topical botulinum toxin A for the treatment of enlarged facial pores: a split-face randomized-controlled pilot study

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230418007
Enrollment
25
Registered
2023-04-18
Start date
2022-11-21
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enlarged facial pores Botulinum toxin Enlarged pores Microneedle

Interventions

Participants will be treated with a microneedle-assisted drug delivery device(POTENZA) while simultaneously being topically applied with a solution containing 16 units of botulinum toxin mixed in 1 ml
Experimental Drug,Placebo Comparator Drug
Microneedling with infusion tip with botulinum toxin A,Microneedling with infusion tip with normal saline

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University
Lead Sponsor
Technicalbiomed Co.,ltd,Merz Aesthetics. Thailand
Collaborator

Eligibility

Sex/Gender
All
Age
25 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Thai descendants 2. There are enlarged pores on both cheeks. By definition, enlarged pores must be visible to the naked eye (visible topographic enlarged facial pores) at a distance of 30 cm and examined by two dermatologists with a consensus.

Exclusion criteria

Exclusion criteria: 1. Pregnant, breastfeeding, or after giving birth for no more than three months or plan to become pregnant during six months. 2. Using vitamin A compounds or chemical peeling agents or injecting botulinum toxin on the cheek area in the last six months 3. History of allergy to anesthetics or botulinum toxin 4. History of hypertrophic scars or keloids 5. Open wounds, infected skin, or skin rashes on the face 6. Having underlying diseases such as diabetes, collagen-related disorders, immunodeficiencies, or having an underlying condition that the researcher considers to be unsafe if participating in the program, such as epilepsy 7. History of regularly using steroids or smoking. 8. History of using anticoagulants, antiplatelet agents, or ginkgo leaf extract. 9. Volunteers with an implanted pacemaker with an implanted metallic device.

Design outcomes

Primary

MeasureTime frame
Pore volume before treatment, 2 weeks, 1 month, 3 months, 6 months after treatment Antera 3D analysis

Secondary

MeasureTime frame
Adverse events 1 week, 2 weeks, 1 month, 3 months, 6 months after treatment Clinical evaluation,Sebum production 2 weeks, 1 month, 3 months, 6 months after treatment Sebumeter

Countries

Thailand

Contacts

Public ContactThrit Hutachoke

Faculty of Medicine Siriraj Hospital, Mahidol University

maxover2@gmail.com0818032865

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026